Partner
Khosla VenturesCheck size: No reliable current personal check range was found. Khosla Ventures invests across company stages and is known for both early technical risk and later follow-on support, but founders should ask Jun about the applicable vehicle, initial ownership, reserves and decision process rather than relying on marketplace estimates.
Jun backs long-horizon technologies at the intersection of biology, healthcare and frontier engineering. His medical training, decade of bench and clinical research, digital-health operating work and company-formation experience support a first-principles lens: take technically difficult risks where a validated breakthrough could materially improve health, then confront clinical evidence, affordability, access, regulation and real-world adoption early.
Scientist or clinician founders with a non-obvious technical insight, a high-consequence unmet need, ambitious long-horizon work, convincing early data, a path to clinical validation, potential for dramatic cost or access improvement, and willingness to solve product, regulatory and reimbursement constraints rather than treating them as downstream details.
No exhaustive personal pass list is published. His public commentary implies weak fit for incremental products without meaningful patient benefit, scientific claims unsupported by reproducible evidence, devices that cannot become portable or affordable enough for real use, and healthcare products whose access, reimbursement, regulatory or clinical-validation path is ignored.
Start with the unmet clinical need and why current care fails. Show the first-principles scientific or engineering insight, reproducible data, development risks, experiment plan, clinical endpoint, regulatory path, manufacturability, cost and reimbursement, patient access and why this team can sustain a long technical journey. Be explicit about what must be true for the result to become a large, practical healthcare business.
Break the moonshot into falsifiable scientific, engineering, clinical, regulatory, manufacturing and adoption milestones, each with a decisive experiment.
Define which patient outcome, accuracy, speed, burden or cost improvement is large enough to change clinical behavior rather than merely publish well.
Assess whether form factor, cost, workflow, infrastructure, reimbursement and distribution let the breakthrough reach patients outside a controlled lab.
Connect mechanism and evidence to product specification, clinical validation, regulatory clearance, manufacturing, buyer, workflow and scalable commercialization.
No writing has been linked yet. Kit can search for posts, interviews, and fund essays worth reading before outreach.
No podcast appearances are linked yet. Ask Kit to check for interviews that reveal how this investor thinks.
Quote coverage is incomplete. Kit can look for direct comments on markets, founders, and investment criteria.
Jun Jeon, MD is a Partner at Khosla Ventures focused on healthcare, biology and frontier technology. He spent more than a decade in bench and clinical research across immuno-oncology, RNA interference, microfluidics, induced pluripotent stem cells, rare disease and clinical trials, supported by NIH IRTA and MRSP fellowships. He worked on business development at Oshi Health, new product opportunities at Octant Bio and healthcare incubation and investing at AlleyCorp. While earning his MD at the University of Pennsylvania, he co-founded Bio Launch, now Nucleate Philadelphia, to move academic science toward market; he previously earned a BS in Chemical and Biomolecular Engineering from Johns Hopkins.